MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.
Around 80 therapeutic antibody programs based on the company’s technologies are currently in development, of which more than 20 are in clinical trials. The company’s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. The proprietary compound MOR202 for the treatment of patients with multiple myeloma is jointly being developed in a collaboration with Celgene. MOR208 is the third proprietary clinical program, also for the treatment of cancer.
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.